Company: PDEX
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001079973-25-001655
Chunk: 20

Company: PRO DEX INC
Filing Date: 2025-10-30
Form: 10-Q
Item: Item 8
Chunk 20
---
are also working to build top-line sales through active proposals of new medical device products with new and existing customers. Our
patented adaptive torque-limiting software has been very well received in the CMF and thoracic markets. Additionally, our latest Pro-Dex
branded product, the Helios driver for CMF applications, featuring our adaptive torque-limiting software, is expected to be released
for production in the second quarter of this fiscal year. Although we anticipate this product will be released in the second quarter
of this fiscal year, and we have had interest in this product, there is no guarantee that our existing customers or new customers will
purchase this new driver.

In
November 2020, we purchased an approximate 25,000 square foot industrial building in Tustin,
California (the “Franklin Property”). This building is located approximately four miles from our Irvine, California headquarters
and was acquired to provide us additional capacity for our expected continued future growth, including anticipated expanded capacity
for the manufacture of batteries and new products. We began operations in the new facility during the fourth quarter of fiscal 2023 and
believe that the additional capacity will allow for our continued expected growth.

In
summary, our current objectives are focused primarily on maintaining our relationships with our current medical device customers, investing
in research and development activities to design unique medical devices as well as Pro-Dex branded drivers to leverage our torque-limiting
software, expanding our manufacturing capacity through the commencement of operations at the Franklin Property, and promoting active
product development proposals to new and existing customers for both orthopedic shavers and screw drivers for a multitude of surgical
applications, while monitoring closely the progress of all these individual endeavors. While we expect revenue growth in the future,
it may not be a consistent trajectory but rather periods of incremental growth that current expenditures are helping to create. However,
there can be no assurance that we will be successful in any of these objectives.

18 

Results of Operations

The
following tables set forth results from continuing operations for the three months ended September 30, 2025 and 2024 (in thousands, except
percentages):

    Three
    Months Ended September 30, 

    2025  
    2024 

    Dollars in thousands 

    % of Net Sales  
       
    % of Net Sales 
  
    Net sales	 
    $18,530  
     100% 
    $14,892  
     100%